SCHEMBL3012372

SCHEMBL3012372

COc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(C)cc4)CC3)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.42
HSD17B10 Q99714 3/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
LMNA P02545 5/20 0.41
ALDH1A1 P00352 5/20 0.41
HPGD P15428 1/20 0.41
GBA1 P04062 1/20 0.40
PKM P14618 2/20 0.40
PTPRB P23467 1/20 0.39
TP53 P04637 4/20 0.39
MAPK1 P28482 2/20 0.39
TAS2R14 Q9NYV8 1/20 0.39
TSHR P16473 1/20 0.39
GPR6 P46095 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PRKAA2 P54646 1/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003985 0.92 LMNA (0.45) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3014556 0.92 MAPT (0.42) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3014608 0.92 MAPT (0.51) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3003810 0.92 GBA1 (0.40) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3010946 0.91 MAPT (0.41) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3006084 0.91 PTPRB (0.41) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL2997684 0.90 GBA1 (0.43) MAPTALDH1A1HPGDGBA1MEN1
SCHEMBL3000443 0.90 MAPT (0.40) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3019144 0.90 KDM4E (0.42) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3010085 0.89 MAPT (0.43) MAPTHSD17B10USP2RECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.